Siemens Catches a Bernstein Tailwind as Healthineers Spin-Off and US Rail Deal Reshape the Narrative

Bernstein raises Siemens price target to €300, citing Healthineers separation timeline, $390M NY signaling deal, and buyback potential as catalysts for a structural re-rating.

The Munich-based industrial conglomerate has been quietly assembling a case for re-rating that goes far beyond the usual cyclical recovery story. With a freshly raised price target from Bernstein Research, a concrete timeline for the Healthineers separation, and a major US signalling contract in the bag, Siemens is presenting investors with a multi-layered catalyst stack that analysts believe the market has yet to fully price in.

Bernstein’s Alasdair Leslie lifted his price target to €300 on Monday, maintaining an “Outperform” rating. His rationale cuts against the grain of recent market anxiety: the sell-off triggered by AI sector jitters, cyclical headwinds and the sheer complexity of Siemens’ sprawling structure has been overdone, in his view. Over the next six to twelve months, he expects a re-rating as two structural drivers take hold — the sharpening of the group’s focus through the Healthineers deconsolidation and the growing scope for further share buybacks.

The separation of Siemens Healthineers is now on a firm timetable. Shareholders will vote on the demerger at the annual general meeting in February 2027, with the plan structured under German transformation law so that Siemens investors receive Healthineers shares directly. Management argues this route maximises value on both sides, leaving Siemens leaner and better positioned to channel capital into industry, digitalisation and artificial intelligence.

The market has already begun to reward the clarity. Siemens shares have rallied more than 20 percent from their March lows, closing Monday at €251.85 after a 3.6 percent gain. That puts the stock within striking distance of its 52-week high of €261.55, though the year-to-date advance of roughly 4.5 percent still lags behind peers such as Schneider Electric and ABB, which have posted gains of 20 to 33 percent. Market observers see this gap as the catch-up potential Leslie flagged in his note.

Underpinning the optimism is a solid operational base. In the first quarter of 2026, orders rose 10 percent to €21.4 billion and revenue climbed 8 percent. For the full year, management targets adjusted earnings per share of €10.70 to €11.10, while the analyst consensus sits at roughly €10.85 on revenue of around €83.7 billion. The next quarterly numbers are due on 13 May, with the book-to-bill ratio serving as a key metric for order momentum.

A fresh contract win in New York adds a further layer of conviction. Siemens Mobility, together with partner L.K. Comstock, has been selected by the Metropolitan Transportation Authority to modernise signalling and control technology on the Fulton-Liberty Lines. The contract, valued at approximately $390 million, will see Siemens deploy its “Trainguard MT” radio-based train control system across 65 kilometres of track, replacing signal equipment that in places is more than a century old. The system will enable train headways of 90 seconds. The agreement runs for 25 years, including maintenance and extension options.

The New York deal is emblematic of a broader trend: Siemens is winning large-scale, long-duration infrastructure contracts that provide revenue visibility well beyond the typical industrial cycle. The Healthineers separation, meanwhile, addresses the conglomerate discount that has long weighed on the stock. Bernstein’s revised target of €300 implies upside of roughly 19 percent from current levels.

For the current financial year, analysts estimate the dividend will rise to around €5.64 per share, up from €5.35 in fiscal 2025. The combination of a clearer corporate structure, a robust order book and a valuation that still reflects lingering scepticism has created what Leslie describes as a compelling entry point — one that the next set of quarterly results on 13 May will either validate or challenge.